Article in Journal of enzyme inhibition and medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
4 citing papers in PubMed, 7 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors at 4 institutions in 2 countries.
Rossella FioravantiDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, Rome, Italy. Laboratory affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti.
Veronica RodriguezDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, Rome, Italy. Laboratory affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti.
Jonatan CaroliDepartment of Biology and Biotechnology, University of Pavia, Pavia, Italy.
Ugo ChianeseDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
Rosaria BenedettiDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
Elisabetta Di BelloDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, Rome, Italy. Laboratory affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti.
Beatrice NoceDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, Rome, Italy. Laboratory affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti.
Clemens ZwergelDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, Rome, Italy. Laboratory affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti.ORCID 0000-0002-3097-0003
Davide CorintiDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, Rome, Italy. Laboratory affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti.
Dolores ViñaCenter for Research in Molecular Medicine and Chronic Disease (CIMUS), Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Universidade de Santiago de Compostela, Santiago de Compostela, Spain.ORCID 0000-0001-5777-1955
Lucia AltucciDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.ORCID 0000-0002-7312-5387
Andrea MatteviDepartment of Biology and Biotechnology, University of Pavia, Pavia, Italy.ORCID 0000-0002-9523-7128
Sergio ValenteDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, Rome, Italy. Laboratory affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti.ORCID 0000-0002-2241-607X
Antonello MaiDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, Rome, Italy. Laboratory affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti.ORCID 0000-0001-9176-2382
Istituto Pasteur · ITUniversity of Campania "Luigi Vanvitelli" · ITUniversity of Pavia · ITUniversidade de Santiago de Compostela · ES
Funding
Histone Lysine deMethylation: Structures, Inhibitions and MechanismsR01GM114306 · NIGMS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHENG, XIAODONG · 2015 to 2018
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Heterocycle-containing tranylcypromine derivatives endowed with high anti-LSD1 activity. · full record | OpenQuestion